Roche’s GLP-1/GIP entering late-stage with competitive efficacy

Among the bright spots in the clinic this week were Phase II results suggesting Roche’s dual GLP-1/GIP agonist has competitive weight loss efficacy.

In the CT388-103 study, weekly injections of 24 mg CT-388 led to placebo-adjusted weight loss of 22.5% at 48 weeks in 469 people with obesity, without reaching an efficacy plateau. ...